בנט סיכם עם פייזר: התרופה החדשה לטיפול בקורונה תגיע ביום רביעי  

And a third option, one so far expected to remain effective against omicron, is in scant supply.

Federal health officials are now moving quickly to stockpile the drug, called sotrovimab, from Vir Biotechnology and GlaxoSmithKline.

Dr. Anthony Fauci, the nation's top infectious disease expert, said the low supply of sotrovimab is "something we need to worry about" in a private call this week between the White House COVID response team and the nation's governors obtained by ABC News.

Recommendation 10: Among patients hospitalized with COVID-19, the IDSA guideline panel recommends against COVID-19 convalescent plasma. (Strong recommendation, Moderate certainty of evidence)

Recommendation 11: Among ambulatory patients with mild to moderate COVID-19, the IDSA guideline panel suggests against COVID-19 convalescent plasma outside of the context of a clinical trial. (Conditional recommendation, Low certainty of evidence)

Paxlovid is not authorized for the pre-exposure or post-exposure prevention of COVID-19 or for initiation of treatment in those requiring hospitalization due to severe or critical COVID-19. Paxlovid is not a substitute for vaccination in individuals for whom COVID-19 vaccination and a booster dose are recommended.

Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations. Paxlovid is administered as three tablets (two tablets of nirmatrelvir and one tablet of ritonavir) taken together orally twice daily for five days, for a total of 30 tablets. Paxlovid is not authorized for use for longer than five consecutive days.